Kymera Therapeutics (KYMR) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Strategic focus and pipeline evolution

• Shifted strategic focus to IMiD, investing in programs and talent over several years, resulting in a robust small molecule pipeline and six clinical programs.

• Halted less promising activities to concentrate on large markets with unmet needs, leveraging protein degradation as a key solution.

• Maintains $1.6 billion in cash, providing runway through 2029 to support ongoing and future clinical development.

STAT6/KT-621 program highlights

• Phase Ib data in atopic dermatitis (AD) and comorbid asthma showed strong STAT6 degradation, biomarker impact, and clinical efficacy comparable or superior to dupilumab.

• FeNO biomarker reductions in both AD and asthma patients demonstrated systemic IL-4/13 pathway inhibition, supporting confidence in phase IIb studies.

• Phase IIb studies in AD and asthma are ongoing, with data expected in the first half and later part of 2027, respectively.

• Long-term safety data from preclinical and clinical studies remain clean, with no significant adverse findings or signals to date.

• Plans to use phase IIb results to launch multiple phase III campaigns across additional type 2 allergic and respiratory diseases.

Market opportunity and positioning

• Type 2 disease market estimated at 140 million patients, with only a fraction currently treated; significant unmet need remains.

• Oral daily therapy with efficacy similar to dupilumab is expected to appeal broadly, not limited to Dupixent failures.

• STAT6 program positioned as a potential major immunology drug if target product profile is achieved.